Black Rock Inc. Rezolute, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Rezolute, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 365,862 shares of RZLT stock, worth $2.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

365,862

Previous 354,916 3.08%

Holding current value

$2.01 Million

Previous $905,000 73.81%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.29 - $5.79 $25,066 - $63,377	10,946 Added 3.08%	365,862 $1.57 Million
Q1 2024 May 10, 2024	BUY	$0.95 - $2.55 $88,155 - $236,627	92,795 Added 35.4%	354,916 $905,000
Q4 2023 Feb 13, 2024	BUY	$0.74 - $1.24 $2,592 - $4,344	3,504 Added 1.35%	262,121 $259,000
Q3 2023 Nov 13, 2023	SELL	$1.32 - $2.1 $5,049 - $8,032	-3,825 Reduced 1.46%	258,617 $341,000
Q2 2023 Aug 11, 2023	BUY	$1.75 - $2.33 $6,655 - $8,860	3,803 Added 1.47%	262,442 $519,000
Q1 2023 May 12, 2023	BUY	$1.79 - $2.87 $3,952 - $6,336	2,208 Added 0.86%	258,639 $496,000
Q4 2022 Feb 13, 2023	BUY	$1.38 - $2.84 $2,031 - $4,180	1,472 Added 0.58%	256,431 $530,000
Q3 2022 Nov 14, 2022	BUY	$2.19 - $3.49 $3,606 - $5,748	1,647 Added 0.65%	254,959 $698,000
Q2 2022 Aug 12, 2022	BUY	$2.6 - $3.85 $602,638 - $892,368	231,784 Added 1076.66%	253,312 $818,000
Q1 2022 May 12, 2022	BUY	$2.27 - $5.1 $4,415 - $9,919	1,945 Added 9.93%	21,528 $72,000
Q4 2021 Feb 10, 2022	BUY	$4.21 - $7.61 $31,208 - $56,412	7,413 Added 60.91%	19,583 $94,000
Q3 2021 Nov 09, 2021	SELL	$7.45 - $13.66 $1,937 - $3,551	-260 Reduced 2.09%	12,170 $91,000
Q2 2021 Aug 11, 2021	BUY	$6.11 - $15.99 $75,947 - $198,755	12,430 New	12,430 $177,000

Others Institutions Holding RZLT

# of Institutions

Shares Held

38.5M

Call Options Held

1.6K

Put Options Held

24.6K

View Full List

About Rezolute, Inc.

Ticker RZLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,600
Market Cap $214M
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...

More about RZLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account